TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05807048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab and Hyaluronidase-fihj
Description: DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) injection for subcutaneous use. Supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Intervention Medication
Description: The following pre-medications will be administered 1-3 hours before each dose of DARZALEX FASPRO:~* Acetaminophen 650 to 1,000 mg orally~* Diphenhydramine 25 to 50 mg (or equivalent) orally or intravenously~* Montelukast 10mg PO prior to DARZALEX FASPRO®.~* Methylprednisolone 100 mg (or equivalent) orally or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Intervention Medication
Description: The following post-medications will be administered:~* Methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO®.~* Patients with a history of chronic obstructive pulmonary disease will be prescribed short and long-acting bronchodilators and inhaled corticosteroids.~* Antiviral prophylaxis for herpes zoster reactivation must be initiated within one week of daratumumab hyaluronidase-fihj administration and continued for 3 months following the end of treatment.
Study: NCT06538974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands-free exoskeleton
Description: During the one-year intervention period, participants will complete at least one exoskeleton session per week (≥36 sessions) with the Atalante X. The additional voluntary year follows the same design. During sessions with the exoskeleton, the patients will perform ambulatory exercises with the device, with a gradual increase of intensity through the sessions.
Study: NCT03634488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea (20mg/kg/day)
Description: Treatment of severe malnutrition in children with SCA in northern Nigeria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-use therapeutic food
Description: Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-use therapeutic food
Description: Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food
Description: Treatment of severe malnutrition in children with and without SCA in northern Nigeria with an additional 500-1000 calories from ready-to-use-therapeutic food
Study: NCT06543017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: This study included 16 male freestyle wrestlers from Sichuan Province, China. Participants were tested at three time points: the first day of slow weight reduction (T1), the first day of rapid weight reduction (T2), and the day before competition (T3), with measurements taken for physiological performance, mental state, and sleep quality.
Study: NCT06521606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary open reduction and internal fixation
Description: The percutaneous pin was used to manipulate the fragment to achieve reduction; then, a lag screw fixation was done by antegrade technique through a stab incision posteriorly and directly over the fragment. The medial fragment was fixed after the reconstruction of the tibial articular surface to facilitate the anatomic reduction of joint fragments. Again, an image intensifier was used to check the reduction and fixation and to avoid errors of penetration of the joint by screws, malalignment, and inadequate reconstruction of the articular surface; then, the necessary changes were adjusted and made. Wide bone defects in six cases of the primary ORIF cohort and eight cases of the two-stage cohort were packed by corticocancellous iliac bone grafts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary external fixator
Description: ). Schanz screws with a 6 mm diameter were used to simulate the gripping points on the tibial crest at the proximal metaphyseal or diaphyseal level and on the medial side of the heel bone. This latter pin was carefully inserted medial to lateral, ensuring the starting point is two cm anterior and proximal to the posteroinferior aspect of the calcaneal tuberosity to avoid injury to the medial neurovascular bundle and prevent injury iatrogenic fracture. Such posterior pin placement better balances the deforming forces of the powerful triceps surae muscles. To prevent equinus contracture and provide additional stability. Medial and lateral side rods were then connected to the pins. Manual traction was applied to the exoskeleton base during ligamentotaxis to distract the joint and realign the fracture; this distraction was then kept in place by tightening the clamps.
Study: NCT05029518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMP-100
Description: In each period, subjects will receive a single dose of SMP-100 on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3), under fasting or fed conditions, followed by 48 hours of PK and safety assessments.
Study: NCT04845750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rodeo Micro Mapping Catheter
Description: The Rodeo Micro Mapping Catheter is used during cryoablation of atrial fibrillation patients for determination of pulmonary vein isolation
Study: NCT05459246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Beginning 1 minute before the start of the procedure, the patients will be watched (30-45 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30-45 minutes).
Study: NCT04857216

Intervention type: DEVICE
Intervention: Perfusion Index
Description: perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients

Intervention type: DEVICE
Intervention: Perfusion Index
Description: perfusion index in the prediction of peripheral block success was previously reported for infraclavicular brachial plexus block, axillary brachial plexus block, interscalene brachial plexus block, and supraclavicular brachial plexus in adult patients
Study: NCT05741736

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: five-days small group-based lifestyle modification program
Description: healthy lifestyle, based on the promotion of a particular dietary pattern, regular physical activity, psychological support, education, and small group intervention results in weight loss
Study: NCT06102967

Intervention type: BEHAVIORAL
Intervention: delirium
Description: Evaluation of delirium using the ICU Patient Ambiguity Assessment Form (CAM-ICU) 1 day, 2 days, 3 days, and 7 days after surgery
Study: NCT05862116

Intervention type: OTHER
Intervention: Survey form
Description: Patients will be asked to fill a survey form that consists of socio-demographic information, Turkish Health Literacy Scale -32, Short Form-36 Health Survey and Oswestry Disability Index.
Study: NCT06538363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Personalized training advice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Education
Description: Generic training advice
Study: NCT04972136

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Bilateral Theta Burst Stimulation
Description: A total of 30 active BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Bilateral Theta Burst Stimulation
Description: A total of 30 sham BL-TBS sessions. Stimulation will begin with right DLPFC (cTBS) followed by left DLPFC (iTBS)
Study: NCT05180344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
Study: NCT05665218

Intervention type: DIAGNOSTIC_TEST
Intervention: right heart catheterization
Description: Right heart catheterization (RHC) is an invasive hemodynamic procedure that allows direct measurement of right-sided cardiac pressures, calculation of cardiac output and pulmonary vascular resistance. It is the gold standard for the diagnosis of pulmonary arterial hypertension. Right heart catheterization is commonly performed by accessing the internal jugular vein (echo-guided access). Swan Ganz catheter with a dedicated thermistor is used to perform RHC; it is advanced through the right heart chambers to measure right atrial, right ventricle, pulmonary artery and pulmonary arterial wedge pressures. Cardiac output is measured using Fick direct, Fick indirect and thermodilution methods.
Study: NCT05507411

Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy
Description: 41.4Gy/23F

Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy
Description: 41.4Gy/23F

Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy
Description: 41.4Gy/23F

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant Chemotherapy
Description: Paclitaxel for Injection （Albumin Bound): 50mg/m\^2 QW Carboplatin: AUC=2 QW

Intervention type: DRUG
Group type: OTHER
Intervention: Immunotherapy
Description: Camrelizumab 200mg Q3W

Intervention type: DRUG
Group type: OTHER
Intervention: Immunotherapy
Description: Camrelizumab 200mg Q3W

Intervention type: DRUG
Group type: OTHER
Intervention: Immunotherapy
Description: Camrelizumab 200mg Q3W
Study: NCT05942508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection + Anlotinib Hydrochloride Capsules
Description: Anlotinib Hydrochloride Capsules: multi-target receptor tyrosine kinase inhibitor; TQB2450 injection: programmed cell death protein 1 (PD-1) human monoclonal antibody
Study: NCT05802459

Intervention type: OTHER
Intervention: EORTC QLQ-C30
Description: central generic questionnaire associated with different disease specific modules

Intervention type: OTHER
Intervention: EORTC QLQ-OG25
Description: module to assess the quality of life in patients with esophagogastric disease.

Intervention type: OTHER
Intervention: GIQLI
Description: Gastrointestinal Quality of Life Index. It is a gastrointestinal quality of life scale.

Intervention type: OTHER
Intervention: SWAL QoL
Description: Swallowing Quality of Life questionnaire. This is a quality of life and quality of attention questionnaire for patients with oropharyngeal dysphagia.

Intervention type: PROCEDURE
Intervention: Videofluoroscopy
Description: It consists of 14 items that represent the oral and pharyngeal function observed in the VDF. It allows to quantify the severity of dysphagia.
Study: NCT05653505

Intervention type: OTHER
Intervention: Remote Ischemic Conditioning
Description: Remote ischaemic conditioning (RIC) refers to a process whereby periods of intermittent ischemia, typically via the cyclical application of a blood pressure cuff to a limb at above systolic pressure, confers systemic protection against ischemia in spatially distinct vascular territories.
Study: NCT05879900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional physical exercises
Description: Functional physical exercises lasting approximately 15 minutes, for 12 weeks or 24 sessions. The exercises take place during physical education classes taught by the physical education teachers in charge of the classes. The place of intervention takes place in full-time schools in the rural area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Education classes
Description: Physical Education classes according their previously planned contents.
Study: NCT05620758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nd YAG laser
Description: patients from those diagnosed with TMD will receive Nd YAG laser 1064 nm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (980 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (980 nm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (940 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (940 nm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (660 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (660 nm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diode laser (635 nm)
Description: patients from those diagnosed with TMD will receive a diode laser (635 nm)
Study: NCT05479864

Intervention type: PROCEDURE
Group type: OTHER
Intervention: anterior cervical corpectomy and fusion
Description: removal of damaged vertebrae and intervertebral disc that are compressing the spinal cord and spinal nerves
Study: NCT04807764

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standing transspinal stimulation followed by robotic gait training
Description: Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation during standing followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lying transspinal stimulation followed by robotic gait training
Description: Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of non-invasive high frequency (e.g. 30 Hz) transcutaneous transspinal stimulation while lying supine on a therapy table followed by 30 minutes of assisted stepping robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standing sham transspinal stimulation followed by robotic gait training
Description: Fifteen people with spinal cord injury will receive 40 daily sessions of 30 minutes of sham transspinal stimulation during standing at an intensity where sensation is absent followed by 30 minutes of robotic gait training. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
Study: NCT06578039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cell
Description: allogeneic umbilical cord-derived mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-derived mesenchymal stem cell
Description: allogeneic umbilical cord-derived mesenchymal stem cell
Study: NCT05151094

Intervention type: OTHER
Intervention: Observation
Description: Observation of clinical outcomes and comparison to non-treated patients
Study: NCT05189483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Enrolled patients will receive 300 mg/m2 of nab-paclitaxel (Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
Study: NCT06575478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuling Yunhua Granules
Description: Fuling Yunhua Granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fuling Yunhua Granules matched placebo
Description: Fuling Yunhua Granules placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihuang Baoyuan Granules
Description: Dihuang Baoyuan Granules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihuang Baoyuan Granules matched placebo
Description: Dihuang Baoyuan Granules placebo
Study: NCT05603871

Intervention type: PROCEDURE
Intervention: ligamentoplasty of ligamentum teres
Description: An addition to the steps of the open reduction, the following were done:~1. Identification of ligamentum teres~2. Ligamentoplasty of ligamentum teres
Study: NCT05189483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Enrolled patients will receive the following treatment: 200 mg of PD-1 inhibitor (camrelizumab; Hengrui Pharmaceutical, Lianyungang, China) via a 30-min intravenous infusion on day 1. The treatment was repeated every three weeks until progressive disease occurrence or unacceptable adverse events.
Study: NCT06008652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-0201
Description: DR-0201 is a bi-specific antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04658446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality-Assisted Indirect Bonding
Description: Virtual Orthodontic attachments are overlaid on top of the patient's teeth using an augmented-reality headset to guide the bracket positioning procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digitally-Asssited Indirect Bonding
Description: 3D printed models with precise brackets positioned as virtually pre-planned. To aid in the transfer of the planned bracket positions to the patient's physical teeth.
Study: NCT04147052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSLEEPms
Description: Participants randomized to iSLEEPms complete daily online sleep diary forms and weekly online educational modules. Modules focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are scored each week, and feedback is provided to participants to guide adjustments to their recommended bedtimes and wake times. Telephone support is available to provide clarification around module content.
Study: NCT04635904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure one-session
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios multiple times while honing in on the most negative aspects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescriptinf one-session
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) o imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery.
Study: NCT06388083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinlarebant
Description: 5 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT06162520

Intervention type: OTHER
Intervention: Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
Description: Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.

Intervention type: OTHER
Intervention: Contrast-enhanced computed tomography (CECT) and 3D morphological analysis
Description: Diagnosis models are established using quantitative morphological characteristics extracted from the 3D reconstructed bile duct from contrast-enhanced computed tomography (CECT) images.
Study: NCT06635343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPRP
Description: In the CPRP group, a chest physiotherapy program was given by the physiotherapist 5 days a week, for 8 weeks, including respiratory control, diaphragmatic breathing, thoracic expansion exercises, and physical activity recommendations, to be applied once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Inspiratuar Muscle Training
Description: In the experimental group inspiratory muscle training was applied. Children in the experimental group started inspiratory muscle training at 30% of the measured intra-oral maximum inspiratory pressure (MIP) value with 30x2 breaths (1 minute rest between repetitions) for 5 days a week for 8 weeks. The training was carried out with MIP every week. The training was continued for a total of 8 weeks with 30% of the new value by re-measuring the MIP value every week The value was measured again and continued at 30% of the new value for a total of 8 weeks. During each inspiratory muscle training session, oxygen saturation data from the index finger were monitored with a pulse oximeter to prevent individuals from experiencing hypoxia